米托蒽醌单独及其联合利妥昔单抗治疗恶性淋巴瘤的临床效果评价

To Evaluate the Clinical Effect of Mitoxantrone Alone and Combined With Rituximab in the Treatment of Malignant Lymphoma

目的研究在治疗恶性淋巴瘤中实行米托蒽醌单独及其联合利妥昔单抗治疗的效果。方法依据患者入院就诊时间将我院2015年3月-2016年3月收治的58例恶性淋巴瘤患者分为治疗组和对照组,对照组单独使用米托蒽醌,治疗组中联合应用米托蒽醌与利妥昔单抗,对比两组患者治疗后不良反应和治疗效果。结果治疗组总有效率、不良反应率优于对照组,P〈0.05,差异具有统计学意义。结论在恶性淋巴瘤治疗中应用联合用药方式比单独使用米托蒽醌效果更明显,能够改善患者的治疗依从性。

Objective To study the implementation of mitoxantrone alone and combined with rituximab in the treatment of malignant lymphoma in effect. Methods According to the patient＇s hospital admission time of 58 cases of malignant lymphoma patients in our hospital from March 2015 to March 2016 were divided into treatment group and control group, the control group alone mitoxantrone combined with mitoxantrone in the treatment group, anthraquinone and rituximab, effect and treatment of adverse reactions were compared between two groups after treatment. Results The total effective rate and adverse reaction rate of the treatment group were better than those of the control group, P0.05, the difference was statistically significant. Conclusion In the treatment of malignant lymphoma in the application of combination is more obvious than the use of mitoxantrone alone, can improve the treatment compliance of patients.